Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 22, 2021

View Archived Issues

RET inhibitor SYHA-1815 induces G1 cell cycle arrest through c-MYC downregulation

Chiesi identifies new discoidin domain-containing receptor inhibitors

Histone-lysine N-methyltransferase 2A inhibitors discovered at Novartis

Esteve patents dual CACNA2D1/SIGMAR1 ligands

Nanjing Chia Tai Tianqing Pharmaceutical divulges AXL inhibitors

New dihydroorotate dehydrogenase inhibitors described by Medshine Discovery

CD123 x CD3 bispecific Dart molecule MGD-024 active with other agents in AML models

OAB-14 restores dysfunction of endosomal-autophagic-lysosomal pathway in APP/PS1 mice

Discovery of a familial intracranial aneurysm gene

Discovery of novel chalcone derivatives for the treatment of neurodegenerative disorders

PSMA-targeted docetaxel conjugate with high antitumor activity and improved toxicity and solubility

IL-27-producing natural regulatory B-1a cells protect from CNS autoimmune diseases

R-107 improves multiorgan functioning in a sheep model of sepsis

Alnylam submits CTA in U.K. for ALN-XDH to treat gout

CIRBP as promising biomarker to identify high-risk patients with IPF

HPIs show promise for treating herpes simplex viral infection in a murine model

Sorriso closes Series A financing to advance pipeline for immune-mediated diseases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 23, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
Psychedelic space expanding on Trump’s EO
BioWorld
Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...